Volume 91 Issue 13 | p. 19 | Concentrates
Issue Date: April 1, 2013

Shire To Purchase SARcode Bioscience

Department: Business
Keywords: pharmaceuticals, acquisiton, ophthamology

Ireland’s Shire will pay $160 million to acquire SARcode Bioscience, a privately owned ophthalmic drug firm based in Brisbane, Calif. The acquisition will give Shire the dry eye disease agent Lifitegrast, which is in Phase III clinical development. The drug is a small-molecule integrin antagonist designed to block a target in the chronic dry eye inflammation cycle. Shire hopes to launch Lifitegrast in the U.S. as early as 2016. Shire . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society